Study guide

Myasthenia testing and treatment

European Board of Ophthalmology Diploma EBOD

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: EBOD Examination, Applications and Regulations

EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals

2 Chapter 2: Physical Optics, Photometry and Lenses

Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid

3 Chapter 3: Instrument Optics, Aberrations and Laser Physics

Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT

4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing

Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses

5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation

Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics

6 Chapter 6: Extraocular Anatomy and Motor Physiology

Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys

7 Chapter 7: Binocular Vision and Amblyopia

Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment

8 Chapter 8: Childhood Assessment and Strabismus Testing

Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts

9 Chapter 9: Esotropia, Exotropia and Vertical Deviations

Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew

10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery

Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles

11 Chapter 11: ROP and Paediatric Ocular Disease

Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding

12 Chapter 12: Ocular Surface Anatomy and Infection

Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis

13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation

Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis

14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies

Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies

15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure

Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency

16 Chapter 16: Surface Reconstruction and Keratoplasty

Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems

17 Chapter 17: Lens Development, Cataract Assessment and Biometry

Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry

18 Chapter 18: IOL Planning and Phacoemulsification

Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques

19 Chapter 19: Cataract Anaesthesia and Surgical Complications

Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO

20 Chapter 20: Corneal and Intraocular Refractive Surgery

Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange

21 Chapter 21: Presbyopia Procedures and Surface Therapeutics

Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin

22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy

Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation

23 Chapter 23: Angle, Disc and Visual-Field Assessment

Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry

24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms

Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure

25 Chapter 25: POAG, Angle Closure and Pigmentary Disease

POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma

26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment

Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers

27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion

Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions

28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy

Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis

29 Chapter 29: Inherited Retina and Electrophysiology

Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina

30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid

AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum

31 Chapter 31: Retinal Breaks and Detachment Repair

PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling

32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma

Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment

33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation

SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation

34 Chapter 34: Infectious Uveitis and Endophthalmitis

Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment

35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy

Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison

36 Chapter 36: Papilloedema, IIH and Afferent Localisation

Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization

37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology

Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies

38 Chapter 38: Central Motor Control and Cranial Nerve Palsies

Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus

39 Chapter 39: Myasthenia and Ocular Myopathy

Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome

40 Chapter 40: Pupillary Pathways and Anisocoria

Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials

41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment

Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation

42 Chapter 42: Lid Repair and Lacrimal Drainage

Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR

43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours

Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma

44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease

Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling

45 Chapter 45: Ocular Trauma and Vascular Systemic Disease

Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease

46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology

Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects

47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations

Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal

Myasthenia testing and treatment

Key Takeaways Explain This Topic AI

Antibody and electrophysiological results must be interpreted with phenotype and test sensitivity.

Historical edrophonium testing is not a routine unsupervised step and carries serious adverse-effect risks.

Treatment and crisis management require neurology coordination, medication safety and assessment of respiratory function.

Last updated: October 2026

  • Diagnostic Testing Ladder in Myasthenia Gravis
  • 1. The Ice Pack Test

The ice pack test is the primary, non-invasive bedside diagnostic modality for myasthenic ptosis:

Physiological Basis: Cooling inhibits the enzymatic degradation kinetics of acetylcholinesterase (AChE) within the synaptic cleft and optimizes the open-time probability of post-synaptic AChRs, allowing acetylcholine to linger and bind more effectively.

Protocol: The vertical palpebral fissure height is measured at baseline. An ice pack (or crushed ice wrapped in a surgical glove) is placed over the closed ptotic eyelid for 2 minutes (or up to 5 minutes if well tolerated). The ice pack is removed, and the palpebral fissure is remeasured immediately.

Diagnostic Threshold: An elevation of ≥ 2 mm \ge 2\text{ mm} ≥ 2 mm in palpebral fissure height represents a positive test (sensitivity ~80%, specificity ~90-95%).

2. Pharmacological Testing: Edrophonium (Tensilon) Test

Edrophonium chloride is a synthetic, short-acting, reversible acetylcholinesterase inhibitor with an onset of action within 30 to 60 seconds and a duration of 5 to 10 minutes:

Historical edrophonium test: A supervised short-acting cholinesterase-inhibitor challenge was formerly used to assess objective improvement. Availability and current use vary; serious bradycardia and respiratory adverse effects require resuscitation capability. It is not a routine unsupervised diagnostic step, and a response alone does not establish myasthenia.

Historical test safety: Edrophonium can cause bradyarrhythmia and bronchospasm. Where this historical test is still used, specialist monitoring and resuscitation capability, including appropriate atropine, are required. It is not a routine unsupervised diagnostic trial; dose and rescue arrangements follow the local protocol.

Current Role: Due to the risk of life-threatening arrhythmias, edrophonium is rarely utilized in modern European centers, having been largely superseded by the ice pack test, serology, and single-fiber electromyography.

3. Serological Assays

AChR Binding Antibodies: Initial serological test. Highly specific (>99%), but positive in only ~50% of pure ocular MG and ~85% of generalized MG.

Anti-MuSK Assays: Indicated in AChR-negative patients. Essential because MuSK-positive patients respond poorly to standard AChE inhibitors and require specialized immunotherapy.

Anti-LRP4 Antibodies: Second-line evaluation in double-seronegative patients.

4. Electrophysiological Testing

Repetitive Nerve Stimulation (RNS): Low-frequency (2 to 3 Hz) supramaximal electrical nerve stimulation is delivered to motor nerves while recording compound muscle action potentials (CMAPs). A progressive decremental response of > 10 % >10\% > 10% between the first and fourth or fifth CMAP waveform confirms post-synaptic neuromuscular block. Sensitivity is low in pure ocular MG (~30%), but high in generalized disease (~75%).

Single-fibre electromyography (SFEMG): Measures variability of neuromuscular transmission ( jitter ) and can detect impulse blocking. It is sensitive for transmission disorders, but performance depends on the muscle, technique and presentation. A normal orbicularis study does not reliably exclude ocular MG in isolated diplopia; increased jitter can also occur in other disorders. Integrate the examination, antibodies and electrophysiology. See the presentation-specific diagnostic study and 2024 prospective jitter study .

5. Mediastinal Imaging: Thymoma Screening

The thymus gland plays a fundamental role in the breakdown of self-tolerance in AChR-positive MG. Contrast-enhanced chest CT or MRI is mandatory in all newly diagnosed myasthenic patients to evaluate the mediastinum:

Thymic Follicular Hyperplasia: Present in approximately 65% of AChR-positive patients (typically young females).

Thymoma: Present in 10% to 15% of patients (typically older males). Thymomas are true epithelial neoplasms that may exhibit local invasion, requiring surgical oncological resection.

The MGTX Trial: The landmark international randomised MGTX trial demonstrated that in non-thymomatous, generalized AChR-positive myasthenia gravis aged 18 to 65 years, transsternal thymectomy significantly improves clinical outcomes, reduces requirements for oral prednisone, and lowers hospital readmission rates over a 3- to 5-year period.

Medical & Immunological Management of Myasthenia Gravis

Therapy in myasthenia gravis is tailored according to whether disease is purely ocular or generalized, antibody status, and disease severity:

Acetylcholinesterase Inhibitors (Symptomatic First-Line):

Pyridostigmine Bromide (Mestinon): Oral, reversible inhibitor of AChE. Standard starting dosage is 60 mg orally three to four times daily (half-life ~3-4 hours). It enhances functional transmission at the NMJ without modifying underlying autoimmunity.

Muscarinic Side Effects: Abdominal cramping, diarrhoea, hyperperistalsis, nausea, increased lacrimation/salivation. Fasciculations are a nicotinic effect, distinct from these muscarinic effects. Treated with oral muscarinic antagonists that do not cross the blood-brain barrier (e.g. propantheline bromide or glycopyrrolate ).

MuSK Caveat: Patients with anti-MuSK myasthenia gravis frequently do not respond to pyridostigmine and may suffer severe paradoxical worsening, muscle cramping, and fasciculations.

Corticosteroids (Immunosuppression):

Oral Prednisolone: Indicated when symptoms remain functionally debilitating despite pyridostigmine or when ocular MG threatens to generalize. Started at a low dose (10-20 mg/day) and titrated upward gradually (by 5-10 mg every week to 1 mg/kg/day) to avoid paradoxical steroid-induced transient exacerbations of myasthenic weakness during the first 7 to 10 days of high-dose therapy.

Steroid-Sparing Immunosuppressants:

Azathioprine: First-line steroid-sparing agent in Europe (dosage 2-3 mg/kg/day). Thiopurine methyltransferase ( TPMT ) enzyme activity must be verified prior to initiation to prevent catastrophic bone marrow aplasia.

Mycophenolate Mofetil: Inhibits inosine monophosphate dehydrogenase; well tolerated with low hepatotoxicity.

Rituximab (Anti-CD20): B-cell depleting monoclonal antibody. Regarded as the treatment of choice for refractory anti-MuSK myasthenia gravis , often achieving prolonged clinical remissions.

Rescue Therapies for Myasthenic Crisis:

Myasthenic Crisis: An acute, life-threatening exacerbation characterized by respiratory failure (diaphragmatic weakness) or severe bulbar failure (aspiration risk), often precipitated by systemic infection, surgery, or abrupt drug withdrawal.

Intravenous Immunoglobulin (IVIG): Administered at 2 g/kg total dose divided over 2 to 5 days .

Therapeutic Plasma Exchange (PLEX): Typically 5 exchanges (3-4 liters per exchange) on alternate days over 10 to 14 days, directly filtering pathogenic autoantibodies from the plasma. PLEX and IVIG are rescue options; choice depends on urgency, comorbidities, vascular access and local expertise. Airway and respiratory assessment take priority.